Abbvie plans to lift $2 billion cap on deals – WSJ
CEO Richard Gonzalez said the company now has the ability “to do more,” in an interview with the WSJ that was published Monday.
The comments come at a time when the drugmaker is starting to face US competition for its blockbuster rheumatoid arthritis drug, Humira, a key revenue driver for years.
The company did not immediately respond to a Reuters request for comment.
Abbvie is hoping to replace the loss of revenue from Humira through its newer immunology drugs Skyrizi and Rinvoqn, and has forecast sales of more than $21 billion from the two products in 2027.
(Reporting by Nandhini Srinivasan in Bengaluru; Editing by Shinjini Ganguli)